论文部分内容阅读
目的分析拉米夫定治疗失代偿期乙型肝炎(乙肝)肝硬化的临床应用效果。方法 60例失代偿期乙肝肝硬化治疗的患者,随机分为对照组和研究组,各30例。对照组给予一般常规性治疗,研究组给予拉米夫定治疗,治疗后检测两组的肝功能[谷丙转氨酶(ALT)、谷草转氨酶(AST)、白蛋白(ALB)、总胆红素(TBIL)、直接胆红素(DBIL)]。结果治疗后,两组患者的各项肝功能指标较治疗前均有改善,且研究组患者的改善程度明显优于对照组,差异均具有统计学意义(P<0.05)。结论对失代偿期乙肝肝硬化患者采用拉米夫定治疗,效果显著,可提高患者的满意度,值得在临床上大力推广使用。
Objective To analyze the clinical effect of lamivudine in the treatment of decompensated hepatitis B (hepatitis B) cirrhosis. Methods Sixty patients with decompensated hepatitis B cirrhosis were randomly divided into control group and study group, with 30 cases in each group. The control group was given conventional treatment. The study group was treated with lamivudine. After treatment, the liver function of two groups was tested [ALT, ALB, ALB and total bilirubin TBIL), direct bilirubin (DBIL)]. Results After treatment, the indexes of liver function of the two groups improved compared with those before treatment, and the improvement of the study group was better than that of the control group, the difference was statistically significant (P <0.05). Conclusions The use of lamivudine in patients with decompensated hepatitis B cirrhosis has significant effect, which can improve patient satisfaction and is worth to be widely used clinically.